



Cancer Research

AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH



October 1, 1998
Volume 58 • Number 19
PP. 4211-4496
ISSN 0008-5472 • CNREA 8



1999 AACR-Pezcoller International Award for Cancer Research

Nomination Deadline Extended to November 2, 1998



Fondazione
PEZCOLLER
Trento - Italy

AACR-Pezcoller International Award Committee

Peter K. Vogt, Ph.D., *Chairperson*, Scripps Research Institute, La Jolla, USA

Franco Cavalli, M.D., Ospedale San Giovanni, Bellinzona, Switzerland

Gertrude B. Elion, D.Sc., Glaxo Wellcome, Inc., Research Triangle Park, USA

Richard D. Kolodner, Ph.D., Ludwig Institute for Cancer Research, La Jolla, USA

Alex Matter, M.D., Novartis Pharma AG, Basel, Switzerland

Marco A. Pierotti, Ph.D., Istituto Nazionale Tumori, Milan, Italy

Masaaki Terada, M.D., D.M.Sc., National Cancer Center Research Institute, Tokyo, Japan

Bengt Westermark, Ph.D., University of Uppsala, Uppsala, Sweden

Ex officio

David M. Livingston, M.D., Dana-Farber Cancer Institute, Boston, USA

Enrico Mihich, M.D., Roswell Park Cancer Institute, Buffalo, USA

The AACR-Pezcoller International Award for Cancer Research is given annually to a scientist who has made a major scientific discovery in the field of cancer, who continues to be active in the field, and whose ongoing work holds promise for future contributions to cancer research. The Pezcoller Foundation was established in 1982 by Professor Alessio Pezcoller, a dedicated Italian surgeon who has made important contributions to medicine during his career and who, through his foresight, vision, and generous gift in support of the formation of the Foundation, stimulated others to make significant advances in cancer research. Over the past decade the Pezcoller Foundation has given a major award for outstanding contributions to cancer and cancer-related biomedical science.

The American Association for Cancer Research (AACR) was founded in 1907 by eleven physicians and scientists dedicated to the conquest of cancer and now has nearly 14,000 members in more than 60 countries who are experts in basic, clinical, and translational cancer research. The mission of the AACR is to foster cancer research; this is accomplished in part through outstanding scientific publications, meetings, and training and educational programs. Because of the commitment of the Foundation and the AACR to scientific excellence in cancer research, these two organizations are collaborating annually on the presentation of the AACR-Pezcoller Award. This jointly sponsored award will strengthen international collaborations and will be a catalyst for advancements in cancer research internationally. The awardee will be selected by an international committee of AACR members appointed by the AACR President along with the agreement of the Council of the Pezcoller Foundation. While normally the Award will be presented to a single investigator, in exceptional cases two individuals may be selected to share the award when their investigations have resulted in related prize-worthy work. The committee will make its selection solely on the basis of the awardee's scientific accomplishments without regard to race, gender, nationality, or religious or political views. The candidate will give an award lecture during the AACR Annual Meeting in Philadelphia, USA (April 10-14, 1999) and will receive the award in an official ceremony at the Foundation's headquarters in Trento, Italy, after the annual meeting. The award consists of an honorarium of US\$75,000 and a commemorative plaque.

The Pezcoller Foundation and the AACR are now soliciting nominations for the 1999 Award. Nominations can be made by any scientist who is now or has been affiliated with an institution engaged in cancer research. Institutions or organizations are not eligible for this award, and candidates may not nominate themselves.

There is no official application form for this award. The nomination package should consist of the following:

- the candidate's curriculum vitae and full list of published works
- an indication of the candidates's most important publications
- a letter of recommendation in English (500 words, maximum) explaining why the candidate is deserving of this prestigious Award. This letter should summarize the candidate's major scientific achievements, indicate which of the candidate's publications best describe these achievements, and explain the impact of these achievements on progress in cancer research.

Nominators are asked to maintain the confidentiality of the nomination process and to refrain from informing the candidate about the nomination.

The deadline for receipt of nominations for the 1999 Award is **November 2, 1998**. Questions about the nomination process should be directed to the AACR via FAX at (215) 440-9322 or E-mail at aacr@aacr.org. Nominations should be submitted to the AACR. Please forward the original nomination letter plus 15 copies of the letter and any accompanying materials to:

Peter K. Vogt, Ph.D., Chairperson, Selection Committee
AACR-Pezcoller International Award for Cancer Research
c/o American Association for Cancer Research
Public Ledger Building, Suite 826
150 S. Independence Mall West
Philadelphia, PA 19106-3483
USA

**The
American-Italian Cancer Foundation**

U.S. Representative of the European School of Oncology

**is pleased to announce
two Fellowships**

in the amount of \$25,000 each

These fellowships are available to young American researchers interested in conducting one year of scientific work at experimental oncology laboratories of the European Institute of Oncology in Milan, Italy. Priority will be given to candidates researching:

- **Tyrosine kinase substrates and mitogenic signaling**
- **Novel protein: protein interaction domains**
- **p27 and p53 tumor suppressors**
- **Genetics of acute leukemias**

Application deadline is February 1, 1999. Requests for application should be addressed to:

American-Italian Cancer Foundation
872 Madison Avenue, Ste. 2B
New York, NY 10021
Tel. 212-628-9090
Fax: 212-517-6089
E-mail: aicfnyc@aol.com

AACR SPECIAL CONFERENCE IN CANCER RESEARCH

New Research Approaches in the Prevention and Cure of Prostate Cancer

December 2-6, 1998
Hyatt Grand Champions Resort
Indian Wells (Palm Springs), CA



*Supported by Major Educational Grants from
Bristol-Myers Squibb Oncology and from
Beckmann Coulter, Inc.*

CONFERENCE CO-CHAIRPERSONS

Jonathan W. Simons / Baltimore, MD
Kenneth J. Pienta / Ann Arbor, MI

CONFERENCE PROGRAM

Keynote Addresses

Andy Grove / Santa Clara, CA
Leroy E. Hood / Seattle, WA
Donald S. Coffey / Baltimore, MD

Heredity and Environment

Elaine A. Ostrander / Seattle, WA
William B. Isaacs / Baltimore, MD
William G. Nelson / Baltimore, MD
Theodore L. DeWeese / Baltimore, MD
Otis W. Brawley / Bethesda, MD

Local Control of Clinical Prostate Cancer

Jeffrey D. Forman / Detroit, MI
Curtis A. Pettaway / Houston, TX

Molecular Pathology

Lance A. Liotta / Bethesda, MD
Jill A. Macoska / Ann Arbor, MI
Robert E. Reiter / Los Angeles, CA

Hormones and Hormone Therapy

Evelyn R. Barrack / Baltimore, MD
Ronald M. Evans / La Jolla, CA
Martin E. Gleave / Vancouver, BC, Canada
June M. Chan / Boston, MA

Prostate Cancer Tumor Biology

Carrie W. Rinker-Schaeffer / Chicago, IL
Norman M. Greenberg / Houston, TX
Robert S. Kerbel / Toronto, Ontario, Canada

New Therapeutic Initiatives for Advanced Disease

Stuart Holden / Santa Monica, CA
Robert E. Wittes / Bethesda, MD
Erkki Ruoslahti / La Jolla, CA
Jonathan W. Simons / Baltimore, MD
Neal Rosen / New York, NY

Growth Factors

Wallace L. McKeehan / Houston, TX
Michael O'Reilly / Boston, MA
Robert H. Getzenberg / Pittsburgh, PA
Ronald A. Morton, Jr. / Houston, TX


Novel Therapeutic Strategies

Kenneth J. Pienta / Ann Arbor, MI
Gerald P. Murphy / Seattle, WA
Martin G. Sanda / Ann Arbor, MI
Alan W. Partin / Baltimore, MD

Additional Talks from Selected Abstracts Submitted by Young Investigators

Information and Application Forms:

American Association for Cancer Research
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
E-mail: meetings@aacr.org
Website: <http://www.aacr.org>



This cover features Harold L. Newmark, Associate Member, Cancer Institute of New Jersey, Adjunct Professor and Consultant, Department of Chemical Biology, College of Pharmacy, Rutgers University, Piscataway, NJ, and Senior Scientist, Strang Cancer Prevention Center, Cornell University Medical College at Rockefeller University, New York, NY. Dr. Newmark's research has been characterized by an imaginative and original approach to his work, yielding major contributions in the varied tasks that he undertook, with an emphasis on cancer research, particularly chemoprevention.

His early career involved industrial research activities, in which he displayed his innovative thinking in the development of novel methods such as studying the effects of vitamins or pharmaceuticals from the multiple perspectives of reliable analytical techniques applicable to animal models or to humans, and then investigating the transport and fate of these nutrients or medications in animal models. He was successful in these industrial activities for over 40 years, leading to over 20 patents. For the last 22 years of his industrial career, he was employed in the pharmaceutical laboratories of Hoffmann-LaRoche, Nutley, NJ, where he was Director of Parenteral and Food and Agriculture Product Development. Allan H. Conney was employed by the same company in research on the mode of action of carcinogens, and he was influential in Dr. Newmark's decision to enter the field of cancer research with a view to developing new approaches to inhibition of carcinogenesis. With his interest in the area of chemoprevention peaked, Dr. Newmark relocated in 1981 to the Ludwig Institute for Cancer Research in Toronto, Ontario, Canada, directed by W. Robert Bruce. As a nutritional biochemist there, he developed novel methods to study the role of dietary factors that might inhibit one or more of the individual steps in carcinogenesis, namely initiation, development, and promotion. Thus, he investigated phenolic compounds from plants present in human diets (rutin, quercetin, curcumin, tea catechins) as preventive agents, as trapping agents for reactive electrophiles or radicals, as antioxidants, and as inhibitors of

arachidonate metabolism (*Can. J. Physiol. Pharmacol.*, 65: 461, 1987).

In conjunction with Michael J. Wargovich, he became interested in the mechanism whereby increased calcium and vitamin D would lower the developmental aspects in colon carcinogenesis generated by high-fat diets (*Cancer Res.*, 51: 3069, 1991; 52: 2067, 1990; *Nutr. Rev.*, 51: 213, 1993). Under development are clinical studies suggesting that increased calcium intake decreases hyperproliferation of epithelial cells in the colon, research performed currently in the laboratories at the Rockefeller University with Martin Lipkin (*J. Cell. Biochem.*, 22(Suppl.): 65, 1995; *J. Natl. Cancer Inst.*, 87: 1275, 1995). Along those lines, Dr. Newmark also observed that increased dietary calcium and vitamin D reduces carcinogenesis in the mammary gland in animal models (*Cancer Res.*, 49: 6300, 1989; *Am. J. Clin. Nutr.*, 54(Suppl): 206, 1991). He and his colleagues developed a so called Western-style stress diet, high in fat and low in calcium and vitamin D, mimicking the U.S. diet (*J. Natl. Cancer Inst.*, 82: 491, 1990; *Am. J. Clin. Nutr.*, 54: 209, 1991; *Carcinogenesis*, 15: 2645, 1994). In rodents, this diet causes hyperproliferation and hyperplasia of epithelial cells in the colon, mammary gland, pancreas, and prostate (*Nutr. Cancer*, 26: 281, 1996; *Cancer Res.*, 56: 4910, 1996; *J. Natl. Cancer Inst.*, 88: 1586, 1996; *Carcinogenesis*, 18: 995, 1997). Fed chronically, such diets induce early precancerous lesions in the colon without any known carcinogen and the underlying mechanisms continue to be investigated (*Carcinogenesis*, 18: 995, 1997). These results parallel epidemiological data suggesting that the dietary habits in the U.S. involve an overly rich macronutrient diet intake.

Dr. Newmark served on a number of advisory panels to the National Cancer Institute, and he has been a member of the American Association for Cancer Research since 1982. He has published more than 120 papers, most of which were developed after his formal "retirement" in 1981. Although he turned 80 years old in the summer of 1998, he is still active in research, dividing his time between the laboratory of Dr. Lipkin at the Strang Cancer Prevention Center, Rockefeller University, and that of Dr. Conney at the Laboratory of Cancer Research, Rutgers University, Piscataway, NJ, and the Cancer Institute of New Jersey, Robert Wood Johnson Hospital Center, New Brunswick, NJ. A special Symposium in Dr. Newmark's honor was held at Rutgers University in 1993 at the time of his 75th birthday.

Early in his career, Dr. Newmark earned B.S. and M.S. degrees in Chemistry from the College of the City of New York and from the Polytechnic Institute of Brooklyn, respectively. He was awarded an honorary D.Sc. degree from Rutgers University in 1998. Part of the citation for this key honor commented on his "boundless energy and infectious enthusiasm for scientific endeavors, particularly in the field of cancer research." Also cited were his "extraordinarily productive career in industry, on various aspects of drug discovery and drug development [that led to] widely used treatments and procedures" and "his continuing devotion to and pioneering investigation of cancer prevention by dietary substances [that] stimulated research worldwide."

We are indebted to Theresa P. Pretlow, Michael J. Wargovich, and Allan H. Conney for their assistance in providing the information and photograph used for this cover feature.

John H. Weisburger